blockers has meant that more patients survive into the later stages of the disease. The clinical challenge ironically then retrogresses to one that involves optimal fl uid balance while preserving renal function. What we may not realise is that the underlying pathophysiology of this "terminal phase" of CHF is poorly understood. The management thereof can be an emotionally and cognitively demanding saga and ultimately there is no consensus amongst the "experts" as to its appropriate care. The cardiorenal syndrome in CHF results from major aberrations in the mutually benefi cial interaction between heart and kidney. It can be seen as a complex interaction between the heart, kidney and vasculature.
The defi nition of worsening renal function remains controversial, with suggestions including a 26.5 umol/l increase in serum creatinine (SCr) above baseline, a rise in SCr above a threshold (221umol/l), a percentage increase from baseline (>25%), or a combination of these factors. (1, 2) Whatever the defi nition, clinically this syndrome is not diffi cult to recognise -the challenge is to fi nd effective therapies and management strategies. Seventy percent of patients admitted for acute deteriorating heart failure have decreased renal function and 20-45% will experience an increase in SCr in excess of 26.5 umol/l while in hospital. (3) Glomerular fi ltration rate (GFR) measures the fi ltration capacity of the kidneys and is considered the best overall index of renal function. GFR is usually estimated by creatinine-based equations that incorporate demographic characteristics, such as age, gender, race and weight to account for differences in muscle mass and hence creatinine generation. The formulae that we use to estimate GFR have their problems (4) 
This formula includes an adjustment for black individuals, allowing for their increased muscle mass. (6) Both these formulae can be used very well for pharmacokinetic purposes. Interestingly, serum creatinine measurements can vary between laboratories. We may therefore still require newer markers of GFR with cystatin C being used as a future good measurement of renal function.
There are 5 classes in the classifi cation of the cardiorenal syndrome (Table 1 ), but this article will concentrate on Class II, although this can be diffi cult to differentiate from Class IV.
THE HEART AND THE KIDNEY
The heart and the kidney are closely linked as regards physiological health. The heart is required to pump blood at a rate commensurate with the requirements of the metabolising tissues. The greatest responsibility for solute and water excretion is borne by the kidney. 
CLASSIC UNDERSTANDING
The classic understanding of the heart-kidney interaction in heart failure is based on an amalgamation of the hemodynamic and neurohormonal approaches to understanding the syndrome. (8) Left ventricular systolic dysfunction results in decreased cardiac output, which sets up the activation of the renin-angiotensin-aldosterone system (RAAS), the sympathetic nervous and the natriuretic peptide systems. Via diminished renal blood fl ow and perfusion, structural renal changes occur that impair renal function and, together with neuro-hormonal activation, causes increased water and sodium retention, vasoconstriction and diminished cardiac performance. These adaptive mechanisms fail to normalise cardiac output including the cost of an increased circulating plasma volume, which then further amplifi es the downward spiral of heart failure begetting heart failure. Diuretic resistance ensues and the cardiorenal syndrome is "born".
EARLY SIGNS OF CARDIO-RENAL INTERACTION

Deranged sodium handling
The classic concepts of the cardiorenal syndrome may be dissolving.
Volpe et al. (9) described the effects of increased sodium intake on GFR, renal plasma fl ow and renal vascular resistance in mild asymptomatic HF. In both normal and mild heart failure subjects, the increased sodium intake (250 mmol/day vs. 100 mmol/day) caused GFR and renal plasma fl ow and fi ltered load of sodium to increase signifi cantly and renal vascular resistance to drop but, while the fractional clearance of water, excretion of potassium and sodium increased in normal subjects, it was signifi cantly reduced in the mild CHF group. These CHF patients had no clinical signs or symptoms of congestion. This inability to excrete a volume load precedes any evidence of reduced cardiac output.
Importantly, after the addition of low doses of enalapril these effects were reversed and "normalised" the response of the mild CHF group to an increased sodium load. Despite normal hemodynamics and increased fi ltered sodium, less sodium was excreted, implying that abnormal sodium retention is seen early in CHF, relating to an abnormality of proximal tubular sodium handling (distal delivery of sodium is decreased in CHF) which is undetectable during normal sodium intake. Enalapril increases the distal delivery of sodium.
Altered glomerular hemodynamics
A test of renal hemodynamic reserve (the angiotensin II / nitric oxide balance) involves the assessment of the glomerular vasodilatory response to an amino acid infusion. In another interesting study, Magri et al. (10) infused amino acid into normal and mild asymptomatic CHF patients. Normally, an amino acid infusion will reduce renal vascular resistance and increase GFR. GFR, effective renal plasma fl ow increased and renal vascular resistance decreased in the normal subjects but not the CHF group. Only after 6 weeks of enalapril (5mg) or losartan (50 mg) administration at 20h00 (without affecting basal systemic or renal hemodynamics) was the "normal response" elicited in the CHF group.
The early loss of renal functional reserve in CHF appears to relate in part anyway, to local angiotensin II production and the intricate balance between angiotensin II and nitric oxide. This led the investigators to conclude that reduced ejection fraction is a poor predictor of cardiac output and renal blood fl ow and that aberrations in the intra-renal renin-angiotensin-aldosterone axis are present early, before the socalled classic theory of hemodynamic compromise plays a role.
Further detracting from the classic theory is the work of Stevenson and
Tillisch. (11) In a short-term hemodynamic study in CHF and performed in the resting state, they showed that stroke volume is often maximal and can be maintained after reducing LV fi lling pressures to normal while keeping systemic vascular resistance stable. During exercise, more volume reserve may be required. This tends to underline too, the different hemodynamics present in acute heart failure vs. CHF. In acute heart failure, fi lling pressures need to be maximised to maintain stroke volume, but in the chronically dilated heart LV fi lling pressures and ventricular volumes cannot be equated. High ventricular volumes can be maintained with normal fi lling pressures.
PREVALENCE
Large HF interventional trials (SOLVD Prevention (SOLVD-P), (12) SOLVD Treatment (SOLVD-T)) (13) have shown that the blood urea/ creatinine ratio (indicating a pre-renal component to the renal dysfunction) is slightly, but signifi cantly lower in those with moderate renal insuffi ciency than those without. In the Treatment trial, no signifi cant difference in this ratio was seen in those with and without renal insuffi ciency.
(1) Interestingly 21% of 3 673 patients in the SOLVD-P trial had a GFR < 60 ml/min. This fi gure is all the more remarkable, as the patients in this trial were NYHA FC I -II. In the SOLVD-T trial, 35% of 2 161 patients had a GFR < 60 ml/min and these were majority Class II patients. (14) In "real life" renal dysfunction may be more common as this category of patient is often excluded from trials. Overall a serum Creatinine > 132 umol/l and a GFR < 60ml/min is seen in approximately 50% of CHF patients.
All this tends to underline the fact that renal dysfunction occurs early in CHF before hemodynamic insults, patients often have preceding decline in GFR before presenting in clinical CHF, implying shared risk factors for 2 independent conditions, but as CHF worsens so does the degree of renal dysfunction. General arteriosclerosis is highly correlated with severity of glomerulosclerosis and of renal arteriosclerosis, probably explaining the difference in prevalence of renal dysfunction amongst different population groups. (6) As a contrast to predominantly "western" patients, in a retrospective analysis of 163 Black African patients with predominantly NYHA FC II/III CHF, only 12% had an eGFR < 60ml/min. (6) This prevalence is considerably lower than that reported in the SOLVD trials. The average age of the South African cohort was younger (48yrs) and concomitant atherosclerotic disease was in all likelihood low, although this was not formally assessed in the analysis. As seen in the recently published CORONA study, (15) the mean entry SCr was 115 umol/l with 24% of entrants having SCr > 130 umol/l. The mean estimated GFR was < 60 ml/min indicating that the majority of patients in CORONA would be classifi ed as having Stage 3 chronic kidney disease. This is despite the mean entry blood pressure being 129/76 and 37% of entrants being NYHA FC II. As has been previously noted, (12) depressed renal function does not appear to be characterized by a low-output state as a signifi cant number of these patients present with elevated blood pressure. Not only is there an association of 2 independent conditions, but a calculated creatinine clearance of < 60 ml / min is independently associated with all cause death, pump failure death and heart failure hospitalizations.
Chronic kidney disease can be seen as catalyst to the development of CHF (16) and CHF itself is also an important aggravating factor for further renal dysfunction by various mechanisms, not all currently understood.
According to the NHANES data, 28% of patients with renal dysfunction have CHF. What is clear, however, is that the classical hemodynamic theory is inadequate to explain (especially in the early phase) the entire cardiorenal syndrome. What appears more pertinent is that LV systolic dysfunction is associated early on with renal dysregulation that is not related to altered hemodynamics primarily, but rather to intra-renal AII/NO imbalance. Adequacy of baseline renal function is an important determinant involved in the progression to the cardiorenal syndrome and the maintenance of good renal function delays progression from LV systolic dysfunction to frank CHF. Once CHF is established, then hemodynamic, infl ammatory, and oxidative stressors all play a role together with effects of medication, salt and fl uid restriction. (17) 126 CARDIORENAL SYNDROME
PROGNOSIS
Pathophysiological mechanisms underlying this reciprocal relationship between the heart and kidneys are still enigmatic. (18) Renal failure increases cardiovascular mortality in HF patients by up to 1% per each 1ml/min decrease in creatinine clearance. (3) Although renal dysfunction predicts all-cause mortality, it is most predictive of death from progressive heart failure. In the ADHERE registry, (19) We have made great strides in the pharmacological management of chronic HF over the last 3 decades. Importantly, however, although we prolong survival with drugs, eventually the patient deteriorates (20) and we are increasingly presented with a very ill patient, hypoperfused, dyspnoeic and with signifi cant and progressive renal dysfunction.
As more patients survive into advanced stages of disease, it is increasingly diffi cult to maintain optimal fl uid balance while preserving renal function.
In the CORONA trial, despite 92% of patients being on an ACEI or ARB, 75% on a beta-blocker and 40% on an aldosterone antagonist, a third of all patients (from both arms of the trial) were dead by two and a half years.
CONCLUSION
The phenomenon of a cardiorenal limit to standard heart failure medications is becoming more obvious as the experience with HF lengthens. Much research needs to be done to further understand the pathophysiology of the cardiorenal syndrome. This may ultimately lead to improved therapy.
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